Aardvark TherapeuticsAARD
13F holders, Q2 2025 (June 30)35holders +8
17new positions
9sold out
1famous investor
$13.52avg. 13F price*
At the end of Q2 2025, 35 institutions reported holding Aardvark Therapeutics Inc. (AARD) in their 13F filings, up 8 from Q1 2025. 17 opened new positions and 9 sold out. The largest holders were Decheng Capital LLC ($53.0M), Citadel Advisors ($17.4M) and Laurion Capital Management LP ($13.4M). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Aardvark Therapeutics Inc.
- CUSIP
- 002942100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 17 | $1.8M |
| Exits | 9 | $7.3M |
All 13F filers, Q1 2025 → Q2 2025: 1,275,480 shares bought and 1,046,135 shares sold, net +229,345 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Decheng Capital LLC | 13.38% | No change | 3,917,299 | $53.0M |
| Citadel Advisors | 0.02% | Add +0.8% | 1,283,732 | $17.4M |
| Laurion Capital Management LP | 1.62% | Add +22.4% | 989,068 | $13.4M |
| Cormorant Asset Management, LP | 0.81% | No change | 800,189 | $10.8M |
| Vanguard Group Inc. | 0.00% | Add +178.6% | 460,977 | $6.2M |
| Silverarc Capital Management, LLC | 0.79% | Add +140.0% | 286,807 | $3.9M |
| Schonfeld Strategic Advisors LLC | 0.03% | Add +94.0% | 279,258 | $3.8M |
| BlackRock, Inc. | 0.00% | Add +996.0% | 205,795 | $2.8M |
| Adage Capital Partners Gp, L.L.C. | 0.00% | Reduce -30.0% | 175,000 | $2.4M |
| Geode Capital Management, LLC | 0.00% | Add +129.7% | 136,927 | $1.9M |
| Cantor Fitzgerald, L. P. | 0.03% | Add +15.0% | 76,682 | $1.0M |
| UBS Group AG | 0.00% | Add +253.1% | 51,924 | $702K |
| Barclays PLC | 0.00% | New | 50,558 | $684K |
| Northern Trust Corp. | 0.00% | Add +222.0% | 45,085 | $610K |
| State Street Corp. | 0.00% | New | 37,312 | $504K |
| BNP Paribas Financial Markets | 0.00% | Add +2.3% | 35,494 | $480K |
| Goldman Sachs Group Inc. | 0.00% | Reduce -8.4% | 18,595 | $251K |
| Charles Schwab Investment Management Inc. | 0.00% | New | 14,240 | $193K |
| Morgan Stanley | 0.00% | Add +304.0% | 8,960 | $121K |
| Bank of America Corp. | 0.00% | Add +72.9% | 7,989 | $108K |
| New York State Common Retirement Fund | 0.00% | New | 7,300 | $99K |
| Deutsche Bank AG | 0.00% | New | 5,725 | $77K |
| Rhumbline Advisers | 0.00% | New | 5,489 | $74K |
| Wells Fargo & Company | 0.00% | New | 3,239 | $44K |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 0.00% | New | 3,091 | $42K |
| JPMorgan Chase & Co. | 0.00% | Reduce -13.7% | 2,677 | $36K |
| Citigroup Inc. | 0.00% | New | 1,962 | $27K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,268 | $17K |
| STRS Ohio | 0.00% | New | 1,100 | $15K |
| Legal & General Group Plc | 0.00% | New | 587 | $8K |
| Ameritas Investment Partners, Inc. | 0.00% | New | 578 | $8K |
| California State Teachers Retirement System | 0.00% | New | 354 | $5K |
| Amalgamated Bank | 0.00% | New | 193 | $3K |
| Royal Bank of Canada | 0.00% | New | 268 | $3K |
| Sterling Capital Management LLC | 0.00% | New | 75 | $1K |
"% of holder's portfolio" is AARD's weight in each manager's 13F, not the share of Aardvark Therapeutics Inc. the manager owns.